Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).

Cargo Therapeutics discontinued its CAR-T treatment firi-cel in Phase 2 study of firi-cel

Sotio Biotech

1/4/2025 | 3 minutes to read

Print
Copy link

CARGO Therapeutics, a clinical-stage biotech company advancing next generation, potentially curative cell therapies for cancer patients, announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy.

In line with this decision, the company will reduce its workforce to extend cash runway and prioritize the advancement of CRG-023 to Phase 1 proof-of-concept data as well as its novel allogeneic platform. Based on an ad hoc analysis of FIRCE-1 prompted by recent safety events, the company believes the results do not support a competitive benefit-risk profile of firi-cel for the intended patient population. While data from 51 patients with at least one post baseline scan demonstrated an overall response rate of 77% and complete response rate (CR) of 43%, the durability of CR at three months was 18%. Safety data indicated 18% of patients developed immune effector cell-associated hemophagocytic lymphohistiocytosis like syndrome (IEC-HS) that were grade 3 or higher, including grade 4 and grade 5 serious adverse events. IEC-HS is a toxicity that is associated with CAR T-cell therapy and firi-cel in other clinical studies. The company is implementing a workforce reduction of approximately 50% to preserve cash. Further, CARGO will continue to advance CRG-023, its tri-specific CAR T, into a Phase 1 dose escalation study and its allogeneic platform to lead vector candidate selection while evaluating its strategic options. With preliminary cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024, the company expects its cash runway to be extended into mid-2028.

DEALS AND FINANCING 

Leveragen announced strategic collaboration with Moonlight Bio to Advance T Cell Therapies 

Leveragen, a biotech company specializing in next-generation genetic models for antibody discovery, announced a strategic collaboration with Moonlight Bio, a biotech pioneering advanced T cell therapies. This partnership aims to develop cutting-edge T cell therapies to address some of the most challenging and difficult-to-treat cancers. The collaboration integrates Leveragen’s proprietary Singularity Sapiens Mouse platform, a groundbreaking tool for generating fully human single-domain antibodies, with Moonlight Bio’s expertise in T cell engineering. Together, the two companies seek to create T cell therapies with enhanced functionality, persistence, and efficacy, overcoming significant barriers in the treatment of solid tumors. Leveragen will spearhead the discovery of fully human single-domain antibodies against therapeutic targets and Moonlight Bio will oversee the preclinical development of T cell therapies. This collaboration highlights Leveragen’s leadership in single-domain antibody discovery and its commitment to advancing immunotherapy through innovative science and transformative applications.

CARsgen introduced Zhuhai SB Xinchuang to accelerate allogeneic CAR-Ts in China 

CARsgen Therapeutics announced reaching agreements with an investment fund managed by Zhuhai Hengqin SB Xinchuang Equity Investment Management Enterprise to jointly invest in UCARsgen Biotech, a China-based new drug discovery biotechnology company focused on allogeneic CAR-T cell therapies for the treatment of hematologic malignancies. UCARsgen has secured the exclusive rights in mainland China for the research, development, manufacture, and commercialization of the following allogeneic CAR-T products from CARsgen Therapeutics: the BCMA-targeted allogeneic CAR-T cell therapy for the treatment of multiple myeloma and plasma cell leukemia and the CD19/CD20 dual-targeted allogeneic CAR-T cell therapy for the treatment of B-cell malignancies. An investment fund managed by Zhuhai SB Xinchuang (currently undergoing registration and filing procedures) subscribed to the newly increased registered capital of UCARsgen for a consideration of RMB 80 million ($11 million), thus retaining an 8% equity stake in the registered capital of UCARsgen upon completion of the transaction, equity stake of CARsgen Therapeutics in UCARsgen will be diluted from 100% to 92%.

Share on social networks

Share on social networks

Print

Copy link